2-D08
目录号 : GC10408
2-D08是一种合成黄酮和具有细胞通透性的小泛素样修饰蛋白（SUMO）抑制剂，也能抑制Axl靶点，IC50为0.49nM。
Cas No.:144707-18-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
2-D08 is a synthetic flavonoid and cell-permeable small ubiquitin-like modifier (SUMO) inhibitor, which also inhibits the Axl target with an IC50 of 0.49nM[1]. Protein SUMOylation is a dynamic post-translational modification involved in various biological processes in cellular homeostasis and development. 2-D08 inhibits SUMOylation by preventing the transfer of SUMO from the UBC9-SUMO thioester to substrates[2]. 2-D08 is commonly used to investigate the role of SUMOylation in various biological pathways and diseases, such as acute myeloid leukemia and demyelinating disorders[3,4].
In vitro, incubation of C2C12 myoblasts with 2-D08 (50, 100μM) for 24h induced significant morphological changes and markedly inhibited cell viability, with the highest dose of 100µM reducing cell viability by up to 20%[5]. Treatment of human uterine leiomyosarcoma (Ut-LMS) SK-LMS-1 and SK-UT-1B cell lines with 2-D08 (10-100μM) for 7 days resulted in a dose-dependent decrease in cell survival fraction and inhibited the colony-forming ability of Ut-LMS cells[6]. Incubation of primary cultured oligodendrocyte precursor cells (OPCs) with 2-D08 (50μM) for 72h significantly increased the phosphorylation level of FYN tyrosine kinase and enhanced the expression of Kir4.1 and MBP proteins[4].
In vivo, administration of 2-D08 (1mg/kg; i.p.) daily, starting 48h after MOG35-55 immunization, significantly alleviated disease severity and promoted weight gain during the acute phase in experimental autoimmune encephalomyelitis (EAE) mice at 20 days post-immunization. 2-D08 (1mg/kg; i.v.) administered daily for 30 days, starting after symptom onset in EAE marmosets, promoted spinal cord myelin repair and improved motor coordination[4]. 2-D08 (10mg/kg; every three days) administered via intratumoral injection to C57BL/6J mice bearing RM-1 tumors for 2 weeks significantly suppressed tumor growth, reduced tumor mass, and increased tumor cell apoptosis[7].
References:
[1] FUJINO N, KUBO H, MACIEWICZ R A. Phenotypic screening identifies Axl kinase as a negative regulator of an alveolar epithelial cell phenotype[J]. Laboratory Investigation, 2017, 97(9): 1047-1062.
[2] KIM Y S, KEYSER S G L, SCHNEEKLOTH J S J. Synthesis of 2’, 3’, 4’-trihydroxyflavone (2-D08), an inhibitor of protein sumoylation[J]. Bioorganic & Medicinal Chemistry Letters, 2014, 24(4): 1094-1097.
[3] ZHOU P, CHEN X, LI M, et al. 2-D08 as a SUMOylation inhibitor induced ROS accumulation mediates apoptosis of acute myeloid leukemia cells possibly through the deSUMOylation of NOX2[J]. Biochemical and Biophysical Research Communications, 2019, 513(4): 1063-1069.
[4] LIU M, JIN S, FU X, et al. Activation of Kir4.1 Channels by 2-D08 Promotes Myelin Repair in Multiple Sclerosis[J]. Advanced Science, 2025: e02032.
[5] LIU H, LEE S M, JOUNG H. 2-D08 treatment regulates C2C12 myoblast proliferation and differentiation via the Erk1/2 and proteasome signaling pathways[J]. Journal of Muscle Research and Cell Motility, 2021, 42(2): 193-202.
[6] JOUNG H, LIU H. 2-D08 mediates notable anticancer effects through multiple cellular pathways in uterine leiomyosarcoma cells[J]. Oncology Reports, 2024, 52(1): 97.
[7] XIAO J, SUN F, WANG Y N, et al. UBC9 deficiency enhances immunostimulatory macrophage activation and subsequent antitumor T cell response in prostate cancer[J]. Journal of Clinical Investigation, 2023, 133(4): e158352.
2-D08是一种合成黄酮和具有细胞通透性的小泛素样修饰蛋白（SUMO）抑制剂，也能抑制Axl靶点，IC50为0.49nM[1]。蛋白质SUMO化是一种动态的翻译后修饰，参与细胞稳态和发育中的多种生物过程，2-D08通过阻止SUMO从UBC9-SUMO硫酯转移到底物来抑制SUMO化[2]。2-D08通常用于研究SUMO化在各种生物途径和疾病（如急性髓系白血病和脱髓鞘疾病）中的作用[3,4]。
在体外，2-D08（50, 100μM）与C2C12成肌细胞孵育24h，细胞形态发生明显改变，且能显著抑制细胞活力，在最高剂量100µM下细胞活力下降幅度最大可达20%[5]。2-D08（10-100μM）处理人子宫平滑肌肉瘤（Ut-LMS）SK-LMS-1和SK-UT-1B细胞系7天，导致细胞存活分数出现剂量依赖性下降，且可抑制Ut-LMS细胞集落形成的能力[6]。2-D08（50μM）与原代培养的少突胶质前体OPCs细胞共孵育72h，显著增加了FYN酪氨酸激酶的磷酸化水平，并增强了Kir4.1和MBP蛋白的表达[4]。
在体内，2-D08（1mg/kg; i.p.）在MOG35-55免疫后48h开始每日给药治疗实验性自身免疫性脑脊髓炎（EAE）小鼠，20天后显著减轻了小鼠EAE急性期的病情严重程度并促进了体重增加。2-D08（1mg/kg; i.v.）在EAE狨猴出现症状后开始给药，连续治疗30天后，促进了脊髓髓鞘的修复并改善了运动协调能力[4]。2-D08（10mg/kg; every three days）通过瘤内注射治疗携带RM-1肿瘤的C57BL/6J小鼠2周，显著抑制了肿瘤生长，减少了肿瘤质量，并增加了肿瘤细胞凋亡[7]。
| Cell experiment [1]: | |
Cell lines | C2C12 (Mouse myoblasts cells) |
Preparation Method | C2C12 cells were plated in 96-well plates (5 × 103 cells/well) overnight under conducive growth conditions and treated with the indicated concentration of 2-D08 (0, 10, 20, 50, and 100μM) for 24h. To measure cell viability, the MTT assay was used to measure the cell proliferation rate. |
Reaction Conditions | 0, 10, 20, 50, and 100μM; 24h |
Applications | Treatment of C2C12 cells with 2-D08 (50, 100μM) for 24h induced distinct morphological changes and significantly inhibited cell viability, with the maximum reduction of 20% observed at the highest dose of 100µM. |
| Animal experiment [2]: | |
Animal models | Adult male C57BL/6J mice model of EAE |
Preparation Method | EAE mice were administered 1mg/kg of 2-D08 via daily intraperitoneal (i.p.) injection, starting 48h after immunization (prophylactic treatment). |
Dosage form | 1mg/kg; once daily; i.p. |
Applications | 2-D08 significantly alleviated disease severity and promoted weight gain during the acute phase of EAE in mice at 20 days post-immunization. |
References: | |
| Cas No. | 144707-18-6 | SDF | |
| 化学名 | 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one | ||
| Canonical SMILES | O=C1C2=CC=CC=C2OC(C3=CC=C(O)C(O)=C3O)=C1 | ||
| 分子式 | C15H10O5 | 分子量 | 270.2 |
| 溶解度 | ≤1mg/ml in ethanol;30mg/ml in DMSO;30mg/ml in dimethyl formamide | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.701 mL | 18.5048 mL | 37.0096 mL |
| 5 mM | 740.2 μL | 3.701 mL | 7.4019 mL |
| 10 mM | 370.1 μL | 1.8505 mL | 3.701 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet